Patent ID: 9475869
Filing Date: 2016-10-25
CPC Classification: A61K,A61P,C07K,C12N

Claim Text:
1. A method for treating a patient who demonstrates a sensitivity to, or an allergic reaction against, a cat, cat dander, cat hair or an extract thereof, or to Fel d1 protein, or for treating at least one symptom or complication associated with a sensitivity to, or allergic reaction against a cat, cat dander, cat hair or an extract thereof, or to Fel d1 protein, comprising administering an effective amount of one or more isolated human monoclonal antibodies or antigen-binding fragments thereof that bind specifically to Fel d1, comprising the three heavy chain complementarity determining regions (HCDR1, HCDR2 and HCDR3) contained within the heavy chain variable region (HCVR) sequence of SEQ ID NO: 18; and the three light chain complementarity determining regions (LCDR1, LCDR2 and LCDR3) contained within the light chain variable region (LCVR) sequence of SEQ ID NO: 26, or a pharmaceutical composition comprising an effective amount of the one or more isolated human monoclonal antibodies or fragments thereof that bind specifically to Fel d1, to a patient in need thereof, wherein the sensitivity to, or an allergic reaction against, a cat, cat dander, cat hair or an extract thereof, or to Fel d1 protein is lessened in severity and/or duration, or at least one symptom or complication associated with the sensitivity to, or allergic reaction against, a cat, cat dander, cat hair or an extract thereof, or to Fel d1 protein is ameliorated, or that a heightened response to Fel d1 protein upon secondary exposure is prevented, or that the frequency and/or duration of, or the severity of the sensitivity to or allergic reaction against, a cat, cat dander, cat hair or an extract thereof, or to Fel d1 protein is reduced following administration of one or more of the isolated human monoclonal antibodies or fragments thereof that bind specifically to Fel d1, or following administration of a composition comprising any one or more of the isolated human monoclonal antibodies or fragments thereof that bind specifically to Fel d1.